Johnson & Johnson Innovative Medicine

About Johnson & Johnson Innovative Medicine

Innovative Medicine at Johnson & Johnson uses patient experiences to inspire science-based innovations addressing complex diseases, developing potential medicines, and championing patients

Key facts

Industry

Pharmaceutical Manufacturing

Company size

10,000+ employees

Revenue

$813M – $6.4BTamtam estimate

Website

innovativemedicine.jnj.com

LinkedIn

linkedin.com/company/jnjinnovativemedicine

Johnson & Johnson Innovative Medicine competitors

• 
  Pfizer

  Developing innovative healthcare therapies

  United States · 10,000+ employees Direct competitor
• 
  Roche

  Personalized healthcare and innovation

  Switzerland · 10,000+ employees Direct competitor
• 
  Novartis

  Developing innovative medicines

  Switzerland · 10,000+ employees Direct competitor
• 
  Merck

  Leading-edge science saves lives

  United States · 10,000+ employees Direct competitor
• 
  Bristol Myers Squibb

  Transforming patients' lives through science

  United States · 10,000+ employees Direct competitor
• 
  AstraZeneca

  Healthcare innovation through science

  United Kingdom · 10,000+ employees Direct competitor

See all 28 competitors →

Jobs at Johnson & Johnson Innovative Medicine

• [Innovative Medicine] JAPAN Business Insights & Analytics Analyst, BI&A Center of ExcellenceChiyoda, Tokyo, Japan · Sep 29, 2026
• Data Product ManagerBogota, D.C., Capital District, Colombia · Sep 11, 2026
• Associate Director, AI Quality And Governance – R&D Data Science & Digital HealthCambridge, MA, United States · Aug 28, 2026

See all 6 openings →

Johnson & Johnson Innovative Medicine in the news

• J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch

  Johnson & Johnson's Innovative Medicine segment anticipates strong Q3 2026 growth driven by oncology, immunology, and neuroscience products, alongside increased contributions from new launches like Inlexzo, Icotyde, and Imaavy, while older drug sales are expected to decline.

  finance.yahoo.com · Oct 2, 2026
• [Interview] Rybrevant expands first-line options in EGFR-mutated lung cancer, but cost limits access in Korea

  Johnson & Johnson Innovative Medicine's Rybrevant offers expanded lung cancer treatment options in Korea, but its high cost and lack of first-line reimbursement significantly limit patient access.

  koreabiomed.com · Sep 25, 2026
• Johnson & Johnson and Myeloma Ireland launch the 2026 ‘Miles for Myeloma’ Challenge in Cork

  Johnson & Johnson and Myeloma Ireland are collaborating on the 'Miles for Myeloma' challenge to raise awareness and support for people with multiple myeloma.

  imt.ie · Sep 22, 2026

See all 20 articles →